- Home
- DYN vs CNTA Comparison
DYN vs CNTA Comparison
Compare DYN & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYN
- CNTA
- Stock Information
- Founded
- DYN 1984
- CNTA 2020
- Country
- DYN United States
- CNTA United Kingdom
- Employees
- DYN N/A
- CNTA N/A
- Industry
- DYN Medicinal Chemicals and Botanical Products
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- DYN Health Care
- CNTA Health Care
- Exchange
- DYN Nasdaq
- CNTA Nasdaq
- Market Cap
- DYN 2.6B
- CNTA 2.2B
- IPO Year
- DYN 2020
- CNTA 2021
- Fundamental
- Price
- DYN $14.01
- CNTA $16.63
- Analyst Decision
- DYN Strong Buy
- CNTA Strong Buy
- Analyst Count
- DYN 10
- CNTA 8
- Target Price
- DYN $50.78
- CNTA $23.00
- AVG Volume (30 Days)
- DYN 2.1M
- CNTA 964.8K
- Earning Date
- DYN 03-04-2025
- CNTA 03-27-2025
- Dividend Yield
- DYN N/A
- CNTA N/A
- EPS Growth
- DYN N/A
- CNTA N/A
- EPS
- DYN N/A
- CNTA N/A
- Revenue
- DYN N/A
- CNTA $6,853,000.00
- Revenue This Year
- DYN N/A
- CNTA N/A
- Revenue Next Year
- DYN N/A
- CNTA N/A
- P/E Ratio
- DYN N/A
- CNTA N/A
- Revenue Growth
- DYN N/A
- CNTA N/A
- 52 Week Low
- DYN $13.07
- CNTA $7.75
- 52 Week High
- DYN $47.45
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- DYN 37.85
- CNTA 48.19
- Support Level
- DYN $13.59
- CNTA $15.50
- Resistance Level
- DYN $14.50
- CNTA $18.55
- Average True Range (ATR)
- DYN 0.98
- CNTA 1.25
- MACD
- DYN 0.32
- CNTA -0.12
- Stochastic Oscillator
- DYN 22.90
- CNTA 31.57
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.